{"entity":{"id":"scalop-2","kind":"trial","name":"SCALOP-2","aka":["SCALOP 2"],"tldr":"SCALOP-2 is the UK follow-on to SCALOP, testing whether a higher radiotherapy dose or the HIV drug nelfinavir improves chemoradiotherapy for pancreatic cancer that cannot be removed; it finished in 2021 and its main results had not appeared in an indexed journal by September 2026.","summary":"SCALOP-2 (ISRCTN50083238, NCT02024009) recruited 159 patients between 2016 and 2021 at 23 UK hospitals from Aberdeen to Colchester, led from the Churchill Cancer Centre in Oxford. After induction gemcitabine and nab-paclitaxel, patients were randomised between standard and high-dose capecitabine-based chemoradiotherapy with or without nelfinavir; the registry lists the trial as completed on 23 June 2021 with progression-free survival and overall survival as primary outcomes. No primary publication was found in Europe PMC on 24 September 2026, so the corpus records the design and status only; with LAP07 and CONKO-007 it is the evidence base for the locally advanced row's statement that chemoradiotherapy is optional.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02024009","url":"https://clinicaltrials.gov/study/NCT02024009"},{"label":"ISRCTN50083238: SCALOP-2","url":"https://www.isrctn.com/ISRCTN50083238"}],"tags":[],"related":[],"cancers":["pancreatic","locally-advanced-pdac"],"sections":[],"technologies":["chemoradiation","imrt-igrt"],"targets":[],"drugs":["capecitabine","gemcitabine-nab-paclitaxel"],"companies":[],"institutions":["cruk"],"pathways":[],"terms":["chemoradiation","pancreatic-trials-open-today"],"trials":["scalop"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry, 23): Oxford (Churchill), Aberdeen, Clatterbridge, Belfast City, Bristol, Addenbrooke's Cambridge, Velindre Cardiff, Colchester and others."],"nct":"NCT02024009","phase":"1/2","setting":"Locally advanced non-metastatic pancreatic cancer at 23 UK centres: induction gemcitabine plus nab-paclitaxel, then randomisation to capecitabine-based chemoradiotherapy at standard (50.4 Gy in 28 fractions) or high dose (60 Gy in 30 fractions), with or without the radiosensitiser nelfinavir, with progression-free survival and overall survival as the primary endpoints","sponsor":"University of Oxford, with Cancer Research UK and Celgene","enrolled":159,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/scalop-2/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"term":[{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"},{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}],"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"}],"trial":[{"id":"scalop","kind":"trial","name":"SCALOP","route":"/trials/scalop/"}]}}